The U.S. Equal Employment Opportunity Commission filed a lawsuit Monday against Eli Lilly and Co. alleging the company refused to hire older workers for sales representative positions.
If you are not happy with the results below please do another search
50 search results for:
Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.
Nemaura and EVERSANA will work together to develop the optimal launch strategy for large-scale adoption of the diabetes management program, including franchising and direct sales to self-insured corporate clients and healthcare insurers.
Japan’s population level immunity to COVID-19 has reached about 90% in major population areas after a recent Omicron wave, though that level of protection is likely to diminish in a matter of months, according to a study published on Tuesday.
The agency put the partial hold after a serious adverse event was seen in a patient during the study.
The lawsuit accused Biogen of directing millions of dollars in kickbacks to doctors to prescribe its MS drugs Avonex, Tysabri and Tecfidera from 2009 to 2014, with kickbacks delivered in the form of “sham” consulting deals and speaker programs as well as lavish dinners and entertainment.
The agency had earlier said Moderna requested authorization for additional batches in light of the current supply issues. It did not provide details on the number of doses cleared.
On the heels of the upcoming major digital therapeutics show in Boston (DTx East), EVERSANA has announced a partnership with Warsaw, Poland-based Prosoma Digital Therapeutics. Together, they will work together to bring the company’s Living Well digital therapy to the U.S. to improve the quality of life and reduce stress, anxiety, and depression symptoms for patients related to a cancer diagnosis.
In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra (duvelisib).
Seagen and LAVA Therapeutics inked a licensing deal for LAVA’s Gammabody platform for solid tumors, which can potentially exceed $700 million.